We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Cox-2 inhibition enhances the activity of sunitinib in human renal cell carcinoma xenografts.
- Authors
Wang, X; Zhang, L; O'Neill, A; Bahamon, B; Alsop, D C; Mier, J W; Goldberg, S N; Signoretti, S; Atkins, M B; Wood, C G; Bhatt, R S
- Abstract
Sunitinib (Su), a tyrosine kinase inhibitor of VEGFR, is effective at producing tumour response in clear cell renal cell carcinoma (cRCC), but resistance to therapy is inevitable. As COX-2 is a known mediator of tumour growth, we explored the potential benefit of COX-2 inhibition in combination with VEGFR inhibition in attempts at delaying tumour progression on Su.
- Publication
British journal of cancer, 2013, Vol 108, Issue 2, p319
- ISSN
1532-1827
- Publication type
Journal Article
- DOI
10.1038/bjc.2012.591